Edwards Lifesciences

Inari Medical Strengthens Senior Leadership Team with Addition of Two Executives

Retrieved on: 
Tuesday, April 2, 2024
Moses Austin, Ohio State University, Edwards Lifesciences, Education, Patient, Global strategy, SVP, Coronary thrombosis, Business development, Radiology, University, Doctors Hospital, Faculty, Senior, Abstract, MD Anderson Cancer Center, Hospital, MitraClip, Baptist Hospital, Interventional radiology, Health, Global marketing

IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), today announced the appointment of Tim Benner as Senior Vice President of U.S.

Key Points: 
  • IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), today announced the appointment of Tim Benner as Senior Vice President of U.S.
  • Dr. Niekamp will be instrumental in advancing Inari’s mission to improve patient care through physician education and new device development.
  • Mr. Benner joins Inari with more than 16 years of senior leadership experience with high-growth and transformational medical technology companies.
  • We are honored to add his talents to our Medical Affairs team,” said Dr. Thomas Tu, Chief Medical Officer of Inari.

Academy Award® Winner Matthew McConaughey Narrates MacGillivray Freeman's 3D Documentary for IMAX® and Giant Screen Theaters "Superhuman Body: World of Medical Marvels"

Retrieved on: 
Tuesday, March 26, 2024
Citadel, First Citizens BancShares, Health, Personality, Organization, CGI, Edwards Lifesciences, Aortic stenosis, Woman, Philosophy, MIT, Patient, Social media, Dazed and Confused, 3D, Leukemia, Richard King Mellon, Life, Cardiovascular disease, Burroughs Wellcome Fund, IMAX, Dallas Buyers Club, MacGillivray Freeman Films, TAVR, Family, Human, Television, Entertainment

LOS ANGELES, March 26, 2024 /PRNewswire/ -- MacGillivray Freeman Films is pleased to announce that Academy Award®-winning actor Matthew McConaughey will narrate the company's newest 3D giant screen film, Superhuman Body: World of Medical Marvels, for release in select IMAX® and giant screen theatres starting April 12, 2024. 

Key Points: 
  • LOS ANGELES, March 26, 2024 /PRNewswire/ -- MacGillivray Freeman Films is pleased to announce that Academy Award®-winning actor Matthew McConaughey will narrate the company's newest 3D giant screen film, Superhuman Body: World of Medical Marvels, for release in select IMAX® and giant screen theatres starting April 12, 2024.
  • Matthew McConaughey narrates "Superhuman Body: World of Medical Marvels" -- hitting IMAX and giant screens April 12!
  • This film will inspire you, move you, empower you, and you'll be amazed by what your superhuman body can do."
  • "We are delighted to have the talented Matthew McConaughey add his distinctive voice to the project."

Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference

Retrieved on: 
Friday, February 23, 2024
Health, Medical Devices, Biometrics, Health Technology, General Health, Cardiology, Biotechnology, Edwards Lifesciences, Conference

Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024.

Key Points: 
  • Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024.
  • Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:30 a.m.
  • ET.
  • A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/ , with an archived version accessible later the same day.

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

Retrieved on: 
Friday, February 2, 2024
Science, Cardiology, Research, Surgery, Health, FDA, Medical Devices, Clinical Trials, Multimedia, NYHA, Mortality, Tricuspid regurgitation, Hospital, MD, TCT, Food and Drug Administration, Edwards Lifesciences, Patient, Columbia University, Food, CE marking, Quality of life, Risk, Tricuspid valve, KCCQ, OMT

Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR).

Key Points: 
  • Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR).
  • The EVOQUE system is indicated for the improvement of health status in patients with symptomatic severe TR despite optimal medical therapy (OMT), for whom tricuspid valve replacement is deemed appropriate by a heart team.
  • “The EVOQUE system is able to replace the native tricuspid valve, virtually eliminating tricuspid regurgitation in a wide range of patients.
  • The EVOQUE system received CE Mark approval in October 2023, making it the world’s first transcatheter valve replacement therapy to receive regulatory approval to treat TR.

Edwards Lifesciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 2, 2024
Health, Other Health, Other Science, Research, Science, Cardiology, Biotechnology, Edwards Lifesciences, Conference

Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2024.

Key Points: 
  • Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2024.
  • Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT.
  • Scott Ullem, chief financial officer, will also participate in the conference.
  • A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/ , with an archived version accessible later the same day.

Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference

Retrieved on: 
Thursday, December 7, 2023
General Health, Health, Cardiology, TAVR, Corporation, NYSE, Tricuspid valve, Investment, Surgery, Percutaneous aortic valve replacement, Patient, CE marking, PASCAL, PROGRESS, Conference, CLASP, Aortic stenosis, Growth, Development, TCT, Edwards Lifesciences, Critical care, Pharmaceutical industry, Nursing, Pet industry, Management

Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s sharpened focus and strategy for longer-term growth, provide an update on its technology pipeline and share financial guidance1 today during its annual investor conference.

Key Points: 
  • Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s sharpened focus and strategy for longer-term growth, provide an update on its technology pipeline and share financial guidance1 today during its annual investor conference.
  • Continued progress across these areas will result in more patients diagnosed and treated with Edwards’ repair and replacement technologies, and a significant long-term growth opportunity.
  • Also in 2024, Edwards expects to accelerate its surgical mitral leadership with the global commercialization of its MITRIS RESILIA valve.
  • During the conference, Edwards’ management will reaffirm the company’s 2023 financial guidance and provide guidance for 2024.

AlphaLab Health Launches Fourth Cohort of Startups to Transform Patient Care

Retrieved on: 
Thursday, December 7, 2023
AHN, Ulcer, Diabetic neuropathy, Allegheny Health Network, Disease, Disability, Patient, Amputation, NW Innovation Works, Obesity, Prostate cancer, Therapy, Mentorship, Diabetes, Partnership, Survival, Growth, PAK1, Hospital, Quality of life, Bariatric surgery, Metastasis, PCA, IW, Edwards Lifesciences, Pharmaceutical industry, Highmark

PITTSBURGH, Dec. 7, 2023 /PRNewswire-PRWeb/ -- AlphaLab Health, a joint program of Innovation Works (IW) and Allegheny Health Network (AHN) to accelerate the growth of healthcare and life sciences startups, today announced the fourth cohort of companies to participate in the program.Six companies were competitively selected to participate in a six-month program that will help them navigate key risk points in the clinical and commercial development of their early-stage companies.

Key Points: 
  • AlphaLab Health, a joint program of Innovation Works (IW) and Allegheny Health Network (AHN) to accelerate the growth of healthcare and life sciences startups, today announced the fourth cohort of companies to participate in the program.
  • PITTSBURGH, Dec. 7, 2023 /PRNewswire-PRWeb/ -- AlphaLab Health, a joint program of Innovation Works (IW) and Allegheny Health Network (AHN) to accelerate the growth of healthcare and life sciences startups, today announced the fourth cohort of companies to participate in the program.
  • This new cohort continues in this innovative vein, and we look forward to seeing how AlphaLab Health amplifies their outcomes.
  • This new cohort continues in this innovative vein, and we look forward to seeing how AlphaLab Health amplifies their outcomes."

LPA Design Studios President Dan Heinfeld Announces Retirement

Retrieved on: 
Thursday, December 7, 2023
Built environment, American Institute of Architects, U.S. Green Building Council, CAE, Premier Automotive Group, Tata Daewoo, DNA, TIDE Academy, Toyota Motor Sales, USA, LPA, National Council, College, Student, Real estate, Irvine Company, Leisure, Ford Motor Company, Edwards Lifesciences, American Institute, County, Architecture, Structure, Committee, Health, Investment company, University, Swinerton, School, Operation, Partnership, LEED, Biophysical environment, Retirement, Growth, Environment, AIA, Smith, Video game, Management, Interior design, Film industry, Renewable energy, Education, Architect

IRVINE, Calif., Dec. 7, 2023 /PRNewswire-PRWeb/ -- LPA Design Studios today announced the upcoming retirement of longtime president Dan Heinfeld, who led the firm's growth from a small, commercial development-focused architecture studio into a nation-leading integrated design practice setting new standards for performance and design excellence.

Key Points: 
  • IRVINE, Calif., Dec. 7, 2023 /PRNewswire-PRWeb/ -- LPA Design Studios today announced the upcoming retirement of longtime president Dan Heinfeld, who led the firm's growth from a small, commercial development-focused architecture studio into a nation-leading integrated design practice setting new standards for performance and design excellence.
  • "I am confident and excited about what this next generation of leaders is going to do at LPA," Heinfeld said.
  • "I was very fortunate to work with a remarkable landowner and builder who understands the value of planning, landscape and design," Heinfeld said.
  • Heinfeld built LPA around the concept that designs could be timeless and do more to cut energy costs and improve health and wellness.

Gryt Health and Iryss Come Together to Empower and Improve the Lives of Patients and their Care Partners

Retrieved on: 
Monday, October 30, 2023
Knowledge, St. Louis Fed Financial Stress Index, Survivor, Health, Heart, Conference, Organization, Entrepreneurship, Edwards Lifesciences, Medicine, Partnership, GVCC, Cancer, Patient, Pharmaceutical industry, Nursing

ROCHESTER, N.Y., Oct. 30, 2023 /PRNewswire-PRWeb/ -- Gryt Health and Iryss are dedicated to transforming the lives of patients and care partners. This partnership represents the intersection of empathy-driven support and cutting-edge technology to holistically enhance the financial journey of patients, survivors, and care partners.

Key Points: 
  • ROCHESTER, N.Y., Oct. 30, 2023 /PRNewswire-PRWeb/ -- Gryt Health and Iryss are dedicated to transforming the lives of patients and care partners.
  • This partnership represents the intersection of empathy-driven support and cutting-edge technology to holistically enhance the financial journey of patients, survivors, and care partners.
  • Through working together, the quilt of support for patients and care partners, the heart of each company's mission, grows.
  • David Craig, Chief Executive Officer of Gryt Health, on the company's mission, "Gryt is a healthcare company that was started by patients and care partners, for patients and care partners.

Mindray's Collaboration with Edwards Lifesciences Marks the First Integration of The FloTrac™ Sensor for Multiparameter Bedside Monitoring

Retrieved on: 
Thursday, October 12, 2023
Pressure, Nursing care plan, Perfusion, Mindray, Health, Patient safety, Anesthesia, Edwards Lifesciences, Patient, Medical device, Pharmaceutical industry

MAHWAH, N.J., Oct. 12, 2023 /PRNewswire/ -- Mindray, a global leader and developer of healthcare solutions and technologies in ultrasound, patient monitoring, and anesthesia, announced a new milestone in their cooperative agreement with Edwards Lifesciences, a global leader in medical innovations for structural heart disease and critical care monitoring. This milestone provides a solution that makes Mindray's BeneVision N-Series the first patient monitoring system to integrate with Edwards FloTrac™ sensor for hemodynamic monitoring in the North American market, following their launch in China in 2022. 

Key Points: 
  • This milestone provides a solution that makes Mindray's BeneVision N-Series the first patient monitoring system to integrate with Edwards FloTrac™ sensor for hemodynamic monitoring in the North American market, following their launch in China in 2022.
  • Mindray's BeneVision N-Series is the first patient monitoring platform to integrate Edwards' FloTrac™ sensor.
  • The continuous monitoring of pressure and flow parameters is essential for managing hemodynamically unstable patients to guide appropriate treatment.
  • This collaboration is a testament to the companies' commitment to improving clinical decision-making, productivity, and ultimately advancing patient care.